aspirin has been researched along with 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Frölich, JC; Ikic, M; Raida, M; Tewes, KS; Tsikas, D | 1 |
Degan, M; Gaino, S; Lechi, A; Meneguzzi, A; Minuz, P; Santonastaso, CL; Soldato, PD; Zuliani, V | 1 |
Badimon, L; Salas, E; Segalés, E; Vilahur, G | 1 |
4 other study(ies) available for aspirin and 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
Article | Year |
---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets.
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Collagen; Cyclic GMP; Cysteine; Fatty Acids, Unsaturated; Glutathione; Guanylate Cyclase; Humans; Hydrazines; Inhibitory Concentration 50; Nitric Oxide; Nitrites; Nitroprusside; Nitroso Compounds; Oxadiazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinoxalines; S-Nitrosoglutathione; S-Nitrosothiols; Thromboxane A2 | 1999 |
NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes.
Topics: Aspirin; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrinolytic Agents; Guanylate Cyclase; Humans; Interleukin-6; Lipopolysaccharides; Monocytes; Nitric Oxide; Oxadiazoles; Quinoxalines; Thromboplastin; Thromboxane B2; Tumor Necrosis Factor-alpha | 2001 |
Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Aspirin; Benzoates; Blood Pressure; Clopidogrel; Collagen; Cyclooxygenase Inhibitors; Drug Evaluation; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; Guanylate Cyclase; Heart Rate; Hemorheology; Imidazoles; Membrane Proteins; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Oxadiazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Quinoxalines; Random Allocation; Receptors, Purinergic P2Y12; rhoA GTP-Binding Protein; Sus scrofa; Thrombosis; Ticlopidine | 2004 |